Shinya Tsuzuki

Shinya Tsuzuki

Auto-generated profile, based on publicly available information

Shinya Tsuzuki

AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
MTMari Terada
Mari Terada
HOHiroshi Ohtsu
Hiroshi Ohtsu
SSSho Saito
Sho Saito
KHKayoko Hayakawa
Kayoko Hayakawa
STShinya Tsuzuki
Shinya Tsuzuki
NONorio Ohmagari
Norio Ohmagari
Objectives To investigate the risk factors contributing to severity on admission. Additionally, risk factors of worst severity and fatality were studied. Moreover, factors were compared based on three points: early severity, worst severity and fatality. Design An observational cohort study using data entered in a Japan nationwide COVID-19 inpatient registry, COVIREGI-JP. Setting As of 28 September 2020, 10480 cases from 802 facilities have been registered. Participating facilities cover a wide range of hospitals where patients with COVID-19 are admitted in Japan. Participants Participants who had a positive test result on any applicable SARS-CoV-2 diagnostic tests were admitted to participating healthcare facilities. A total of 3829 cases were identified from 16 January to 31 May 2020, of which 3376 cases were included in this study. Primary and secondary outcome measures Primary outcome was severe or nonsevere on admission, determined by the requirement of mechanical ventilation or oxygen therapy, SpO2 or respiratory rate. Secondary outcome was the worst severity during hospitalisation, judged by the requirement of oxygen and/orinvasive mechanical ventilation/extracorporeal membrane oxygenation. Results Risk factors for severity on admission were older age, men, cardiovascular disease, chronic respiratory disease, diabetes, obesity and hypertension. Cerebrovascular disease, liver disease, renal disease or dialysis, solid tumour and hyperlipidaemia did not influence severity on admission; however, it influenced worst severity. Fatality rates for obesity, hypertension and hyperlipidaemia were relatively lower. Conclusions This study segregated the comorbidities influencing severity and death. It is possible that risk factors for severity on admission, worst severity and fatality are not consistent and may be propelled by different factors. Specifically, while hypertension, hyperlipidaemia and obesity had major effect on worst severity, their impact was mild on fatality in the Japanese population. Some studies contradict our results; therefore, detailed analyses, considering in-hospital treatments, are needed for validation. Trial registration number UMIN000039873. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045453

1 April 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
STShinya Tsuzuki
Shinya Tsuzuki
NMNobuaki Matsunaga
Nobuaki Matsunaga
KYKoji Yahara
Koji Yahara
YGYoshiaki Gu
Yoshiaki Gu
KHKayoko Hayakawa
Kayoko Hayakawa
NONorio Ohmagari
Norio Ohmagari
There has been scarce evidence about deaths due to blood stream infection (BSI) in Japan so far. The main objective of this study is to understand the epidemiological trend of deaths caused by BSIs due to Staphylococcus aureus and Escherichia coli including Methicillin-resistant S. aureus (MRSA) and fluoroquinolone-resistant E. coli (FQREC) at national level. We annually estimated the number of BSI caused by S. aureus and E. coli between 2011 and 2017 across Japan using comprehensive data of bacterial culturing and drug susceptibilities collected in Japan Nosocomial Infection Surveillance (JANIS). The number of death was estimated by using BSI mortality obtained from previous studies in Japan. The number of BSI death attributable to S. aureus was estimated to 17,412 in 2011 and 17,157 in 2017, respectively, out of the whole population (126.8 million) in Japan. Among them, cases attributed to MRSA accounted for 5924 (34.0%) in 2011, and decreased to 4224 (24.6%) cases in 2017. On the other hand, the number of BSI death attributable to E. coli was estimated to 9044 in 2011 and increased to 14,016 in 2017. Among them, cases attributed to FQREC accounted for 2045 (22.6%) in 2011 and increased to 3915 (27.9%) cases in 2017. The number of BSI death attributable to MRSA has been decreasing and that attributable to FQREC has been increasing. This study provides the first annual estimate of disease burden of BSI caused by antimicrobial resistant (AMR) bacteria in Japan, and basis for formulating health policy to deal with AMR.

1 June 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MUMugen Ujiie
Mugen Ujiie
STShinya Tsuzuki
Shinya Tsuzuki
NONorio Ohmagari
Norio Ohmagari
To evaluate the influence of temperature on the infectivity of COVID-19 in Japan. We evaluated the relationship between the accumulated number of patients per 1,000,000 population and the average temperature in February 2020 in each prefecture by Poisson regression analysis. We introduced the monthly number of inbound visitors from China in January 2020 in each prefecture as an additional explanatory variable in the model. Both monthly inbound visitors from China in January 2020 and mean temperature in February 2020 are associated with the cumulative number of COVID-19 case on March 16, 2020. Our analysis showed a possible association between low temperature and increased risk of COVID-19 infection. Further evaluation would be desirable at a global level.

19 August 2022 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
STShinya Tsuzuki
Shinya Tsuzuki
YMYusuke Miyazato
Yusuke Miyazato
MTMari Terada
Mari Terada
SMShinichiro Morioka
Shinichiro Morioka
NONorio Ohmagari
Norio Ohmagari
PBPhilippe Beutels
Philippe Beutels
Background: The empirical basis for a quantitative assessment of the disease burden imposed by long-COVID is currently scant. We aimed to inform the disease burden caused by long-COVID in Japan. Methods: We conducted a cross sectional self-report questionnaire survey. The questionnaire was mailed to 526 eligible patients, who were recovered from acute COVID-19 in April 2021. Answers were classified into two groups; participants who have no symptom and those who have any ongoing prolonged symptoms that lasted longer than four weeks at the time of the survey. We estimated the average treatment effect (ATE) of ongoing prolonged symptoms on EQ-VAS and EQ-5D-3L questionnaire using inverse probability weighting. In addition to symptom prolongation, we investigated whether other factors (including demography, lifestyle, and acute severity) were associated with low EQ-VAS and EQ-5D-3L values, by multivariable linear regression. Results: 349 participants reported no symptoms and 108 reported any symptoms at the time of the survey. The participants who reported any symptoms showed a lower average value on the EQ-VAS (69.9 vs 82.8, respectively) and on the EQ-5D-3L (0.85 vs 0.96, respectively) than those reporting no symptoms considering the ATE of ongoing prolonged symptoms. The ATE of ongoing prolonged symptoms on EQ-VAS was − 12.9 [95% CI − 15.9 to − 9.8], and on the EQ-5D-3L it was − 0.11 [95% CI − 0.13 to − 0.09], implying prolonged symptoms have a negative impact on patients’ EQ-VAS and EQ-5D-3L score. In multivariable linear regression, only having prolonged symptoms was associated with lower scores (− 11.7 [95% CI − 15.0 to − 8.5] for EQ-VAS and − 0.10 [95% CI − 0.13 to − 0.08] for EQ-5D-3L). Conclusions: Due to their long duration, long-COVID symptoms represent a substantial disease burden expressed in impact on health-related quality of life.

10 August 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
SMS. Morioka
S. Morioka
STS. Tsuzuki
S. Tsuzuki
MSM. Suzuki
M. Suzuki
MTMari Terada
Mari Terada
MAM. Akashi
M. Akashi
NON. Ohmagari
N. Ohmagari

10 August 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KSKensuke Shoji
Kensuke Shoji
TATakayuki Akiyama
Takayuki Akiyama
STShinya Tsuzuki
Shinya Tsuzuki
NMNobuaki Matsunaga
Nobuaki Matsunaga
YAYusuke Asai
Yusuke Asai
NONorio Ohmagari
Norio Ohmagari